Valuation: Autolus Therapeutics plc

Market Cap 452M 397M 366M 339M 642M 43.32B 655M 4.4B 1.71B 21.2B 1.7B 1.66B 73.59B P/E 2026 *
-1.92x
P/E 2027 * -2.71x
Enterprise Value 413M 362M 334M 309M 586M 39.54B 597M 4.02B 1.56B 19.35B 1.55B 1.52B 67.16B EV / Sales 2026 *
3.21x
EV / Sales 2027 * 2.62x
Free-Float
3.32%
Yield 2026 *
-
Yield 2027 * -
1 day+5.59%
1 week+7.59%
Current month+6.25%
1 month+16.44%
3 months+14.09%
6 months-10.99%
Current year-14.57%
1 week 1.58
Extreme 1.575
1.74
1 month 1.44
Extreme 1.44
1.74
Current year 1.18
Extreme 1.175
2.07
1 year 1.18
Extreme 1.175
2.7
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 31/08/2014
Chief Executive Officer 61 29/02/2016
Director of Finance/CFO 56 06/08/2023
Director TitleAgeSince
Chairman 61 30/09/2014
Director/Board Member 78 31/07/2014
Director/Board Member 71 28/02/2018
Date Insider Type Main position Quantity % Market Cap.
06-28Free

Director

79,167 0.0477%
06-28Free

Director

79,167 0.0477%
06-28Free

Chairman

79,167 0.0477%
Change 5-day change 1-year change 3-year change Capi.($)
+5.59%+7.59%-27.97%-31.45% 452M
-1.97%+6.11%+21.02%-4.27% 67.44B
-2.01%-3.57%+46.21%+217.46% 53.98B
-4.15%+36.30%+36.30%+36.30% 41.77B
+1.62%+7.36%-48.13%-52.14% 41.15B
-7.48%+1.79%+126.80%-37.92% 29.28B
-2.60%-4.47%+49.01%-27.16% 29.58B
-0.67%+3.03%+73.28%+88.92% 23.43B
+0.35%+1.52%+5.35%+191.26% 19.11B
-1.33%+1.11%+66.11%+132.74% 16.82B
Average -1.24%+2.29%+34.80%+51.37% 32.3B
Weighted average by Cap. -2.06%+1.53%+35.69%+52.21%

Financials

2026 *2027 *
Net sales 129M 113M 104M 96.21M 182M 12.31B 186M 1.25B 486M 6.02B 483M 472M 20.91B 191M 168M 155M 143M 271M 18.29B 276M 1.86B 722M 8.95B 717M 701M 31.06B
Net income -242M -212M -196M -181M -343M -23.13B -349M -2.35B -914M -11.32B -907M -887M -39.29B -184M -161M -149M -138M -261M -17.6B -266M -1.79B -695M -8.61B -690M -675M -29.89B
Net Debt -39.53M -34.67M -32.01M -29.58M -56.07M -3.79B -57.19M -385M -150M -1.85B -148M -145M -6.43B 48.41M 42.46M 39.2M 36.23M 68.66M 4.64B 70.04M 471M 183M 2.27B 182M 178M 7.87B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
08/07/26 US$1.700 +5.59% 1,673,442
07/07/26 US$1.610 -1.23% 755,323
06/07/26 US$1.630 +3.16% 1,039,035
02/07/26 US$1.580 0.00% 1,442,602
01/07/26 US$1.580 -1.25% 698,723
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.700USD
Average target price
8.550USD
Spread / Average Target
+402.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock